We investigated BDH1/2 and OXCT1/2 expression in several cancer cell lines and tested this hypothesis with two representative cell lines that had low and high expression levels of these key ketone body catabolism enzymes in vivo and in vitro. The gene discussed is BDH1; the disease is cancer.